Recently targeted therapy has made significant progress in ovarian cancer, such as the vascular endothelial growth factor (VEGF) targeting drug bevacizumab and the p-oly-ADP-ribose polymerase (PARP) inhibitor olaparib [5–7]. Here, VEGFA is linked to ovarian carcinoma.